PubMed Health⌕ Search

Biomedical subjects

Jeffrey A Mattes

Publications and source records attributed to Jeffrey A Mattes.

6 recordsLinked to original sources
PubMed2005

Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial.

OBJECTIVE: Impulsive aggression is a common clinically significant symptom, but there are few controlled studies evaluating drug treatment. This study evaluated oxcarbazepine in patients with impulsive aggression and whether diagnosis or other baseline characteristics predict response. METHOD: Eligible outpatients had clinically significant impulsive aggression, without other psychiatric symptoms clearly requiring treatment. Patients were randomized to oxcarbazepine or placebo, double-blind, for 10 weeks, at a variable dose increasing to 1200 mg/d if tolerated and to 2400 mg/d if aggression persisted. Primary outcome measures were (1) change in a Global Overt Aggression rating derived from the Overt Aggression Scale-Modified and (2) patient-rated global improvement. RESULTS: Of 48 patients, 24 per group, 9 dropped out due to adverse events, but 45 completed at least 4 weeks on double-blind medication. Analyses showed consistent evidence of benefit from oxcarbazepine, compared with placebo, on both primary efficacy measures and most secondary measures. There were no significant interactions between diagnosis or other baseline characteristics and differential response to oxcarbazepine or placebo. CONCLUSION: Oxcarbazepine appears to benefit adults with clinically significant impulsive aggression.

Adult↗
PubMedDate not supplied

Antidepressant-induced rapid cycling: another perspective.

BACKGROUND: Depressive symptoms are the main cause of morbidity in bipolar patients, but concern about antidepressant-induced rapid cycling has limited antidepressant use in such patients. This paper evaluates the validity and the prevalence of antidepressant-induced rapid cycling. METHODS: The literature regarding antidepressant induced rapid cycling is reviewed, focusing on two issues: 1) does antidepressant-induced rapid cycling occur only in patients who become manic or hypomanic on antidepressants; 2) can the apparent shortening of cycle length on antidepressants be attributable simply to the fact that antidepressants alleviate depression and can precipitate mania or hypomania. RESULTS: The suggestion that antidepressants can induce rapid cycling is derived primarily from patients who become manic or hypomanic on antidepressants. The fact that antidepressants alleviate depression and precipitate mania can explain most of the available data, without invoking the poorly defined concept of antidepressant-induced rapid cycling. CONCLUSIONS: Bipolar patients who are stable on mood stabilizers, who don't become manic or hypomanic on anti-depressants, can be safely treated with antidepressants without excessive concern about inducing rapid cycling.

Anticonvulsants↗